ES2294018T3 - Compuestos y metodos para el tratamiento y diagnostico de la infeccion con clamidias. - Google Patents
Compuestos y metodos para el tratamiento y diagnostico de la infeccion con clamidias. Download PDFInfo
- Publication number
- ES2294018T3 ES2294018T3 ES01959114T ES01959114T ES2294018T3 ES 2294018 T3 ES2294018 T3 ES 2294018T3 ES 01959114 T ES01959114 T ES 01959114T ES 01959114 T ES01959114 T ES 01959114T ES 2294018 T3 ES2294018 T3 ES 2294018T3
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- polypeptide
- seq
- baselineskip
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000015181 infectious disease Diseases 0.000 title claims description 20
- 238000011282 treatment Methods 0.000 title claims description 14
- 238000003745 diagnosis Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 title description 69
- 150000001875 compounds Chemical class 0.000 title description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 201
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 186
- 229920001184 polypeptide Polymers 0.000 claims abstract description 184
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 84
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 84
- 239000002157 polynucleotide Substances 0.000 claims abstract description 84
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 230000028993 immune response Effects 0.000 claims abstract description 20
- 229960005486 vaccine Drugs 0.000 claims description 31
- 206010061041 Chlamydial infection Diseases 0.000 claims description 23
- 201000000902 chlamydia Diseases 0.000 claims description 23
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 239000003022 immunostimulating agent Substances 0.000 claims description 6
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 6
- 241001185363 Chlamydiae Species 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 86
- 239000000427 antigen Substances 0.000 description 85
- 108091007433 antigens Proteins 0.000 description 85
- 102000036639 antigens Human genes 0.000 description 85
- 241000606153 Chlamydia trachomatis Species 0.000 description 83
- 102000004169 proteins and genes Human genes 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 52
- 241000606161 Chlamydia Species 0.000 description 51
- 230000014509 gene expression Effects 0.000 description 46
- 108091028043 Nucleic acid sequence Proteins 0.000 description 32
- 239000000523 sample Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 239000002671 adjuvant Substances 0.000 description 30
- 239000013598 vector Substances 0.000 description 30
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 239000013604 expression vector Substances 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 23
- 102100026357 40S ribosomal protein S13 Human genes 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 229940038705 chlamydia trachomatis Drugs 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 230000003053 immunization Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 206010061218 Inflammation Diseases 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 15
- 241001647372 Chlamydia pneumoniae Species 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 125000005647 linker group Chemical group 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 230000009696 proliferative response Effects 0.000 description 12
- 102000009016 Cholera Toxin Human genes 0.000 description 11
- 108010049048 Cholera Toxin Proteins 0.000 description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- 241000700618 Vaccinia virus Species 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 210000003101 oviduct Anatomy 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 101150077194 CAP1 gene Proteins 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000011735 C3H mouse Methods 0.000 description 7
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000002611 ovarian Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 125000006853 reporter group Chemical group 0.000 description 5
- 210000005000 reproductive tract Anatomy 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 241001647378 Chlamydia psittaci Species 0.000 description 4
- 241000498849 Chlamydiales Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000759568 Corixa Species 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 4
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 101710188053 Protein D Proteins 0.000 description 3
- 101710132893 Resolvase Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- -1 salts of primary Chemical class 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 208000007190 Chlamydia Infections Diseases 0.000 description 2
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 208000028512 chlamydia infectious disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000014828 interferon-gamma production Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000011049 pearl Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 101150106828 pmpD gene Proteins 0.000 description 2
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical group 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101150116940 AGPS gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- HJXSYJVCMUOUNY-SRVKXCTJSA-N Cys-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N HJXSYJVCMUOUNY-SRVKXCTJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 208000026351 Fallopian Tube disease Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001503524 Ovine adenovirus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 102000010983 Ribosomal protein S13 Human genes 0.000 description 1
- 108050001197 Ribosomal protein S13 Proteins 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 244000247617 Teramnus labialis var. labialis Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000008350 antigen-specific antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 101150077981 groEL gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 238000011392 neighbor-joining method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 150000003726 retinal derivatives Chemical class 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464835—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/620,412 US6448234B1 (en) | 1998-12-08 | 2000-07-20 | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US620412 | 2000-07-20 | ||
| US841132 | 2001-04-23 | ||
| US09/841,132 US20020061848A1 (en) | 2000-07-20 | 2001-04-23 | Compounds and methods for treatment and diagnosis of chlamydial infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2294018T3 true ES2294018T3 (es) | 2008-04-01 |
Family
ID=27088713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01959114T Expired - Lifetime ES2294018T3 (es) | 2000-07-20 | 2001-07-20 | Compuestos y metodos para el tratamiento y diagnostico de la infeccion con clamidias. |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US20020061848A1 (fr) |
| EP (1) | EP1307564B1 (fr) |
| JP (1) | JP2004513622A (fr) |
| KR (1) | KR20030016423A (fr) |
| CN (1) | CN100467600C (fr) |
| AT (1) | ATE373092T1 (fr) |
| AU (2) | AU8070201A (fr) |
| BR (1) | BR0112602A (fr) |
| CA (1) | CA2418282A1 (fr) |
| CY (1) | CY1107796T1 (fr) |
| CZ (1) | CZ2003480A3 (fr) |
| DE (1) | DE60130468T2 (fr) |
| DK (1) | DK1307564T3 (fr) |
| ES (1) | ES2294018T3 (fr) |
| HK (1) | HK1067381A1 (fr) |
| HU (1) | HUP0400477A3 (fr) |
| IL (2) | IL153904A0 (fr) |
| MX (1) | MXPA03000564A (fr) |
| NO (1) | NO20030252L (fr) |
| NZ (3) | NZ541013A (fr) |
| PL (1) | PL209107B1 (fr) |
| PT (1) | PT1307564E (fr) |
| RU (2) | RU2410394C2 (fr) |
| WO (1) | WO2002008267A2 (fr) |
| ZA (1) | ZA200300719B (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| WO2000011180A1 (fr) | 1998-08-20 | 2000-03-02 | Connaught Laboratories Limited | MOLECULES D'ACIDE NUCLEIQUE CODANT LA PROTEINE POMP91A DE $i(CHLAMYDIA) |
| WO2000011181A1 (fr) | 1998-08-20 | 2000-03-02 | Connaught Laboratories Limited | MOLECULES D'ACIDE NUCLEIQUE CODANT LA PROTEINE MEMBRANE D'INCLUSION C DE $i(CHLAMYDIA) |
| US6649370B1 (en) | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20020094340A1 (en) | 1998-12-01 | 2002-07-18 | Andrew D. Murdin | Chlamydia antigens and corresponding dna thereof |
| EP1144642B1 (fr) | 1998-12-08 | 2010-05-26 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'infections par le chlamydia |
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6555115B1 (en) * | 1998-12-08 | 2003-04-29 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20080213264A1 (en) * | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US7297341B1 (en) | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| CA2356057A1 (fr) | 1998-12-28 | 2000-07-06 | Aventis Pasteur Limited | Antigenes a chlamydia, fragments d'adn correspondants et leurs utilisations |
| GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
| MXPA01009256A (es) | 1999-03-12 | 2003-07-14 | Aventis Pasteur | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. |
| CA2373021A1 (fr) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci |
| DE60037900T2 (de) | 1999-09-20 | 2009-02-12 | Sanofi Pasteur Ltd., Toronto | Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| CA2395499C (fr) | 1999-12-22 | 2011-10-25 | Aventis Pasteur Limited | Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations |
| CA2407114A1 (fr) | 2000-04-21 | 2001-11-01 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia |
| US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| AU2001258105A1 (en) | 2000-05-08 | 2001-11-20 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| JP2004502415A (ja) | 2000-07-03 | 2004-01-29 | カイロン エセ．ピー．アー． | Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化 |
| US7731980B2 (en) * | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
| US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
| US20030059896A1 (en) * | 2000-12-21 | 2003-03-27 | Shire Biochem Inc. | Novel chlamydia antigens and corresponding DNA fragments |
| GB2370838A (en) * | 2001-01-06 | 2002-07-10 | Benedikt Timmerman | Immunogenic complex |
| ATE406912T1 (de) | 2001-12-12 | 2008-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia tracheomatis |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| CN1812809A (zh) * | 2003-06-26 | 2006-08-02 | 希龙公司 | 用于沙眼衣原体的免疫原性组合物 |
| EP1689867A4 (fr) * | 2003-11-20 | 2007-08-22 | Sanofi Pasteur Ltd | Immunisation contre les infections a chlamydia |
| US8541007B2 (en) | 2005-03-31 | 2013-09-24 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
| EA201001322A1 (ru) * | 2005-03-31 | 2011-02-28 | Глаксосмитклайн Байолоджикалс С.А. | Вакцины против хламидиоза |
| AU2006259858A1 (en) * | 2005-05-12 | 2006-12-28 | Novartis Vaccines And Diagnostics S.R.L. | Immunogenic compositions for Chlamydia trachomatis |
| WO2007030879A1 (fr) * | 2005-09-13 | 2007-03-22 | Diatech Pty Ltd | Marqueurs diagnostiques et leurs utilisations |
| EP1981905B1 (fr) * | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccin contre chlamydia |
| EP1970708A1 (fr) * | 2007-03-07 | 2008-09-17 | Mikrogen Molekularbiologische Entwicklungs-GmbH | Biopuce et procédé destiné à la vérification sélective d'infections à chlamydiose |
| US20100310593A1 (en) * | 2007-06-14 | 2010-12-09 | Emergent Product Development Gaithersburg Inc. | Vaccines Against Chlamydia Infection |
| AU2008284352A1 (en) * | 2007-08-03 | 2009-02-12 | President And Fellows Of Harvard College | Chlamydia antigens |
| EP2722056A1 (fr) * | 2007-12-03 | 2014-04-23 | President and Fellows of Harvard College | CT062, une antigènes de Chlamydia |
| RU2011140508A (ru) | 2009-03-06 | 2013-04-20 | Новартис Аг | Антигены хламидии |
| US9458513B2 (en) | 2010-03-23 | 2016-10-04 | Wako Pure Chemical Industries, Ltd. | Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same |
| JP2013545448A (ja) * | 2010-10-20 | 2013-12-26 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | クラミジア抗原及びその使用 |
| US20130095487A1 (en) * | 2011-10-18 | 2013-04-18 | University Of South Florida | Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections |
| US9481714B2 (en) * | 2012-12-05 | 2016-11-01 | Thevax Genetics Vaccine Co., Ltd. | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses |
| CN113801191B (zh) * | 2021-08-18 | 2022-05-17 | 南京大学 | 一种检测衣原体的多肽探针及其应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118469A (en) * | 1976-04-27 | 1978-10-03 | Research Corporation | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) |
| US4497899A (en) * | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Chlamydia trachomatis antigens |
| US4497900A (en) | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Neisseria gonorrhoeae antigens |
| US4497863A (en) * | 1984-03-07 | 1985-02-05 | Milliken Research Corporation | Laminated weft insertion fabric |
| EP0192033B1 (fr) | 1985-01-14 | 1996-09-25 | Chiron Corporation | Protéine principale de la membrane externe de Chlamydia |
| US5785973A (en) * | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| EP0348725A3 (fr) | 1988-06-29 | 1990-10-24 | Miles Inc. | Epitode spécifique de l'espèce de chlamydia trachomatis et les anticorps le reconnaissant |
| EP0628570A1 (fr) * | 1989-02-17 | 1994-12-14 | Chiron Mimotopes Pty. Ltd. | Procédé pour l'utilisation et la préparation des peptides |
| US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
| US5166053A (en) * | 1990-02-23 | 1992-11-24 | Miles Inc. | Specimen adequacy control for chlamydia assays |
| JP3018553B2 (ja) * | 1990-05-08 | 2000-03-13 | 日立化成工業株式会社 | クラミジア・トラコマティス抗体測定方法及びクラミジア・トラコマティス感染症診断用製剤 |
| US5725863A (en) | 1991-09-06 | 1998-03-10 | The United States Of America As Represented By The Secretary Of Agriculture | Polypeptides useful in prevention of chlamydia infection |
| SG90042A1 (en) | 1992-06-25 | 2002-07-23 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
| EP0662083A1 (fr) | 1992-09-18 | 1995-07-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccin a peptide synthetique contre le chlamydia trachomatis |
| US5549978A (en) * | 1992-10-30 | 1996-08-27 | Kabushiki Kaisha Toshiba | Magnetoresistance effect element |
| US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| CN100365017C (zh) | 1994-09-20 | 2008-01-30 | 日立化成工业株式会社 | 肺炎衣原体抗原多肽 |
| GB9506863D0 (en) * | 1995-04-03 | 1995-05-24 | Smithkline Beecham Biolog | Vaccines |
| GB9626864D0 (en) | 1996-12-24 | 1997-02-12 | Smithkline Beecham Biolog | Vaccine |
| GB9516293D0 (en) | 1995-08-09 | 1995-10-11 | Immunova Ltee | Novel peptides and their use as vaccines |
| CN1223589A (zh) * | 1996-05-06 | 1999-07-21 | 美国拜尔公司 | 包含鹦鹉热衣原体的猫疫苗及其制备方法 |
| BR9712971A (pt) | 1996-07-12 | 2002-05-07 | Univ Manitoba | Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica |
| US6464979B1 (en) | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
| US7459524B1 (en) * | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| JP4249279B2 (ja) | 1997-10-22 | 2009-04-02 | デンカ生研株式会社 | クラミジア・トラコマティス主要外膜蛋白質及びその製造方法、並びにクラミジア・トラコマティスの抗体測定方法及び抗体測定試薬 |
| ATE480625T1 (de) * | 1997-11-21 | 2010-09-15 | Merck Serono Biodevelopment | Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion |
| JP2002536958A (ja) | 1997-11-21 | 2002-11-05 | ジェンセット | Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用 |
| US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
| KR100769103B1 (ko) * | 1997-11-28 | 2007-10-23 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
| CN1163602C (zh) | 1998-04-07 | 2004-08-25 | 科里克萨公司 | 结核杆菌抗原融合蛋白及其应用 |
| WO2000023105A2 (fr) * | 1998-10-16 | 2000-04-27 | Smithkline Beecham Biologicals S.A. | Produits d'addition et vaccins |
| US6607730B1 (en) | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| EP1133572A4 (fr) | 1998-11-12 | 2005-06-15 | Univ California | Sequence genomique de chlamydia pneumoniae |
| US20080213264A1 (en) | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP1144642B1 (fr) * | 1998-12-08 | 2010-05-26 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'infections par le chlamydia |
| US6432916B1 (en) * | 1998-12-08 | 2002-08-13 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6565856B1 (en) * | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6447779B1 (en) * | 1998-12-08 | 2002-09-10 | Corixa Corporation | Compounds for the diagnosis of Chlamydial infection |
| US6166177A (en) * | 1998-12-08 | 2000-12-26 | Corixa Corporation | Compounds and methods for the treatment and diagnosis of chlamydial infection |
| US6555115B1 (en) * | 1998-12-08 | 2003-04-29 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6448234B1 (en) * | 1998-12-08 | 2002-09-10 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| GB9902555D0 (en) | 1999-02-05 | 1999-03-24 | Neutec Pharma Plc | Medicament |
| MXPA01009256A (es) | 1999-03-12 | 2003-07-14 | Aventis Pasteur | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. |
| CA2373021A1 (fr) | 1999-05-03 | 2000-11-09 | Aventis Pasteur Limited | Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci |
| US6811783B1 (en) | 1999-09-07 | 2004-11-02 | Aventis Pasteur Limited | Immunogenic compositions for protection against chlamydial infection |
| DE60037900T2 (de) | 1999-09-20 | 2009-02-12 | Sanofi Pasteur Ltd., Toronto | Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| CA2906516C (fr) | 1999-09-28 | 2017-03-07 | Geneohm Sciences Canada Inc. | Acides nucleiques et methodes de detection de streptocoque |
| WO2001040757A2 (fr) * | 1999-10-14 | 2001-06-07 | University Of Utah Research Foundation | Cavites optiques resonnantes destinees a des biodetecteurs a grande sensibilite et a haut rendement et procedes utilisant ces biodetecteurs |
| WO2001035992A1 (fr) | 1999-11-19 | 2001-05-25 | Michigan State University | Vaccins recombines contre les chlamydia |
| CA2395499C (fr) | 1999-12-22 | 2011-10-25 | Aventis Pasteur Limited | Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations |
| US20010048927A1 (en) * | 2000-02-01 | 2001-12-06 | Richard Stephens | Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia |
| US20020146776A1 (en) * | 2000-04-21 | 2002-10-10 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| CA2407114A1 (fr) * | 2000-04-21 | 2001-11-01 | Corixa Corporation | Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia |
| AU2001258105A1 (en) | 2000-05-08 | 2001-11-20 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| EP1290720A1 (fr) * | 2000-06-16 | 2003-03-12 | Applied Materials, Inc. | Nettoyeur carrousel reconfigurable integre pour nettoyage au mouille ou a sec d'un substrat |
| JP2004502415A (ja) | 2000-07-03 | 2004-01-29 | カイロン エセ．ピー．アー． | Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化 |
| EP1301726A1 (fr) * | 2000-07-20 | 2003-04-16 | ZF FRIEDRICHSHAFEN Aktiengesellschaft | Embrayage a une seule surface de friction exempt de bague glissante et a commande electromagnetique |
| US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
| US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
| GB0103169D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| WO2002077183A2 (fr) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification de genes essentiels dans des microorganismes |
| WO2002079244A2 (fr) | 2001-03-30 | 2002-10-10 | University Of Manitoba | Facteur d'activite a chlamydia du type protease responsable de la degradation du facteur de transcription de l'hote |
| US20030199438A1 (en) * | 2001-04-09 | 2003-10-23 | Shaw Allan Christian | Method for identification of proteins from intracellular bacteria |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| ATE406912T1 (de) * | 2001-12-12 | 2008-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia tracheomatis |
| US7105171B2 (en) * | 2002-03-07 | 2006-09-12 | The Regents Of The University Of California | Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| CN1812809A (zh) * | 2003-06-26 | 2006-08-02 | 希龙公司 | 用于沙眼衣原体的免疫原性组合物 |
| FR2869057B1 (fr) * | 2004-04-16 | 2006-06-02 | Piscines Desjoyaux Sa Sa | Dispositif pour la realisation d'un haut de chainage d'un escalier |
| PT1812058E (pt) | 2004-10-25 | 2012-09-17 | Statens Seruminstitut | Antigénios de chlamydia trachomatis para vacina e utilização em diagnóstico |
| US8541007B2 (en) * | 2005-03-31 | 2013-09-24 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
| EA201001322A1 (ru) * | 2005-03-31 | 2011-02-28 | Глаксосмитклайн Байолоджикалс С.А. | Вакцины против хламидиоза |
| AU2006259858A1 (en) * | 2005-05-12 | 2006-12-28 | Novartis Vaccines And Diagnostics S.R.L. | Immunogenic compositions for Chlamydia trachomatis |
| WO2007110700A2 (fr) * | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, Srl. | antigenes chlamydia |
| EP1981905B1 (fr) * | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccin contre chlamydia |
| US20080124338A1 (en) * | 2006-09-22 | 2008-05-29 | The Scripps Research Institute | Methods for treatment of inflammatory disease and chlamydia infectious disease |
| AU2007304199A1 (en) | 2006-10-04 | 2008-04-10 | Corixa Corporation | Vaccines against Chlamydial infection |
| US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
| JP2012505212A (ja) * | 2008-10-09 | 2012-03-01 | ボード・オヴ・リージェンツ，ユニヴァーシティ・オヴ・テキサス・システム | クラミジア感染および疾患の診断および治療のためのクラミジア抗原に関する方法および組成物 |
| US20110293664A1 (en) * | 2008-12-17 | 2011-12-01 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
| RU2011140508A (ru) * | 2009-03-06 | 2013-04-20 | Новартис Аг | Антигены хламидии |
| EP2544715A2 (fr) * | 2010-03-09 | 2013-01-16 | Board Of Regents, University Of Texas System | Procédés et compositions pour antigènes de chlamydia dans le diagnostic et le traitement d'infections et de maladies à chlamydia |
-
2001
- 2001-04-23 US US09/841,132 patent/US20020061848A1/en not_active Abandoned
- 2001-07-20 AT AT01959114T patent/ATE373092T1/de active
- 2001-07-20 CA CA002418282A patent/CA2418282A1/fr not_active Abandoned
- 2001-07-20 NZ NZ541013A patent/NZ541013A/xx not_active IP Right Cessation
- 2001-07-20 MX MXPA03000564A patent/MXPA03000564A/es active IP Right Grant
- 2001-07-20 PT PT01959114T patent/PT1307564E/pt unknown
- 2001-07-20 AU AU8070201A patent/AU8070201A/xx active Pending
- 2001-07-20 IL IL15390401A patent/IL153904A0/xx unknown
- 2001-07-20 DK DK01959114T patent/DK1307564T3/da active
- 2001-07-20 PL PL365951A patent/PL209107B1/pl not_active IP Right Cessation
- 2001-07-20 BR BR0112602-4A patent/BR0112602A/pt not_active Application Discontinuation
- 2001-07-20 AU AU2001280702A patent/AU2001280702B8/en not_active Ceased
- 2001-07-20 CN CNB018148484A patent/CN100467600C/zh not_active Expired - Fee Related
- 2001-07-20 KR KR10-2003-7000885A patent/KR20030016423A/ko not_active Application Discontinuation
- 2001-07-20 EP EP01959114A patent/EP1307564B1/fr not_active Expired - Lifetime
- 2001-07-20 HU HU0400477A patent/HUP0400477A3/hu unknown
- 2001-07-20 JP JP2002514171A patent/JP2004513622A/ja active Pending
- 2001-07-20 WO PCT/US2001/023121 patent/WO2002008267A2/fr active IP Right Grant
- 2001-07-20 RU RU2006120003/10A patent/RU2410394C2/ru not_active IP Right Cessation
- 2001-07-20 NZ NZ549873A patent/NZ549873A/xx not_active IP Right Cessation
- 2001-07-20 CZ CZ2003480A patent/CZ2003480A3/cs unknown
- 2001-07-20 DE DE60130468T patent/DE60130468T2/de not_active Expired - Lifetime
- 2001-07-20 RU RU2003104976/13A patent/RU2003104976A/ru not_active Application Discontinuation
- 2001-07-20 ES ES01959114T patent/ES2294018T3/es not_active Expired - Lifetime
- 2001-07-20 NZ NZ523628A patent/NZ523628A/en not_active IP Right Cessation
-
2003
- 2003-01-13 IL IL153904A patent/IL153904A/en not_active IP Right Cessation
- 2003-01-17 NO NO20030252A patent/NO20030252L/no not_active Application Discontinuation
- 2003-01-27 ZA ZA200300719A patent/ZA200300719B/en unknown
-
2004
- 2004-06-18 US US10/872,155 patent/US7462357B2/en not_active Expired - Fee Related
- 2004-10-14 HK HK04107907.3A patent/HK1067381A1/xx not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/928,855 patent/US20080317772A1/en not_active Abandoned
- 2007-10-30 US US11/929,672 patent/US20090035296A1/en not_active Abandoned
- 2007-10-30 US US11/928,432 patent/US20090028887A1/en not_active Abandoned
- 2007-10-30 US US11/929,620 patent/US20080181918A1/en not_active Abandoned
- 2007-10-30 US US11/928,873 patent/US8263089B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,665 patent/US8052975B2/en not_active Expired - Fee Related
- 2007-11-12 CY CY20071101457T patent/CY1107796T1/el unknown
-
2011
- 2011-09-30 US US13/250,137 patent/US20120114684A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2294018T3 (es) | Compuestos y metodos para el tratamiento y diagnostico de la infeccion con clamidias. | |
| ES2346832T3 (es) | Compuestos y metodos para el tratamiento y el diagnostico de una infeccion clamidial. | |
| ES2303525T3 (es) | Compuestos y metodos para el tratamiento y diagnostico de infeccion por chlamydia. | |
| ES2324529T3 (es) | Compuestos para inmunoterapia y diagnostico de la tuberculosis. | |
| ES2311027T3 (es) | Composiciones y metodos para la inmunoterapia especifica de wt1. | |
| JP4695763B2 (ja) | クラミジア抗原および対応するｄｎａ断片ならびにその使用 | |
| US8916168B2 (en) | Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis | |
| ES2321039T3 (es) | Compuestos para inmunoterapia y diagnosis de tuberculosis y metodos para su uso. | |
| JP4864264B2 (ja) | クラミジア抗原および対応するｄｎａ断片ならびにその使用 | |
| KR20020073136A (ko) | 클라미디아 감염을 치료 및 진단하기 위한 화합물 및 방법 | |
| MXPA01009256A (es) | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. | |
| JP2002530052A (ja) | クラミジア抗原および対応するｄｎａ断片ならびにその使用 | |
| JP2002525028A (ja) | Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントおよびそれらの使用 | |
| US20080213264A1 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
| ES2316627T3 (es) | Polipeptidos de moraxella (branhamella) catarrhalis. | |
| JP2002524034A (ja) | Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントおよびそれらの使用 | |
| JP2003512017A (ja) | クラミジア抗原および対応するｄｎａ断片ならびにその使用 | |
| JP2002525027A (ja) | Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントならびにそれらの使用 | |
| MXPA01006663A (es) | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. | |
| JP2002531095A (ja) | クラミジア抗原および対応するｄｎａ断片ならびにその使用 | |
| JP2002524035A (ja) | Ｃｈｌａｍｙｄｉａ抗原および対応するＤＮＡフラグメントならびにそれらの使用 | |
| KR20010033132A (ko) | 미코박테리움 바카이에서 유도한 조성물 및 이의 이용방법 | |
| MXPA01006576A (en) | Chlamydia | |
| MXPA01005617A (en) | Chlamydia | |
| MXPA01005616A (en) | Chlamydia |